Moreover, we recently demonstrated that NKX6.1 methylation was an independent indicator of 5-year disease-free survival in stage II CRC patients receiving adjuvant chemotherapy [29,30]. This evidence concerns the gene NKX6-1 and colorectal carcinoma.